5.16 USD
+0.05 (+0.98%)
5.16 USD
0 (0%)
We assign a fundamental rating of 6 out of 10 to CVAC. CVAC was compared to 534 industry peers in the Biotechnology industry. CVAC has an excellent financial health rating, but there are some minor concerns on its profitability. CVAC is not valued too expensively and it also shows a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year CVAC was profitable.
In the past year CVAC had a positive cash flow from operations.
In the past 5 years CVAC reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: CVAC reported negative operating cash flow in multiple years.
1.2 Ratios
CVAC's Return On Assets of 28.11% is amongst the best of the industry. CVAC outperforms 97.75% of its industry peers.
CVAC's Return On Equity of 33.02% is amongst the best of the industry. CVAC outperforms 97.94% of its industry peers.
The Return On Invested Capital of CVAC (28.35%) is better than 98.88% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.11% | ||
| ROE | 33.02% | ||
| ROIC | 28.35% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Profit Margin, with a value of 37.93%, CVAC belongs to the top of the industry, outperforming 97.00% of the companies in the same industry.
CVAC has a better Operating Margin (40.58%) than 98.69% of its industry peers.
With an excellent Gross Margin value of 94.81%, CVAC belongs to the best of the industry, outperforming 94.57% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 40.58% | ||
| PM (TTM) | 37.93% | ||
| GM | 94.81% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), CVAC is creating value.
Compared to 1 year ago, CVAC has about the same amount of shares outstanding.
Compared to 5 years ago, CVAC has more shares outstanding
The debt/assets ratio for CVAC has been reduced compared to a year ago.
2.2 Solvency
CVAC has an Altman-Z score of 9.28. This indicates that CVAC is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 9.28, CVAC belongs to the best of the industry, outperforming 82.40% of the companies in the same industry.
The Debt to FCF ratio of CVAC is 0.18, which is an excellent value as it means it would take CVAC, only 0.18 years of fcf income to pay off all of its debts.
CVAC has a Debt to FCF ratio of 0.18. This is amongst the best in the industry. CVAC outperforms 95.32% of its industry peers.
CVAC has a Debt/Equity ratio of 0.05. This is a healthy value indicating a solid balance between debt and equity.
The Debt to Equity ratio of CVAC (0.05) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.18 | ||
| Altman-Z | 9.28 |
ROIC/WACC3.95
WACC7.18%
2.3 Liquidity
CVAC has a Current Ratio of 6.17. This indicates that CVAC is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 6.17, CVAC is in the better half of the industry, outperforming 64.42% of the companies in the same industry.
CVAC has a Quick Ratio of 6.16. This indicates that CVAC is financially healthy and has no problem in meeting its short term obligations.
CVAC's Quick ratio of 6.16 is fine compared to the rest of the industry. CVAC outperforms 65.92% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 6.17 | ||
| Quick Ratio | 6.16 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 170.16% over the past year.
The Revenue has grown by 675.15% in the past year. This is a very strong growth!
CVAC shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 98.42% yearly.
EPS 1Y (TTM)170.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
Revenue 1Y (TTM)675.15%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-91.38%
3.2 Future
The Earnings Per Share is expected to decrease by -22.50% on average over the next years. This is quite bad
CVAC is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -10.88% yearly.
EPS Next Y-170.56%
EPS Next 2Y-63.78%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue Next Year-86.75%
Revenue Next 2Y-59.56%
Revenue Next 3Y-30.85%
Revenue Next 5Y-10.88%
3.3 Evolution
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 5.11, the valuation of CVAC can be described as very cheap.
Based on the Price/Earnings ratio, CVAC is valued cheaply inside the industry as 99.06% of the companies are valued more expensively.
When comparing the Price/Earnings ratio of CVAC to the average of the S&P500 Index (26.37), we can say CVAC is valued rather cheaply.
The Forward Price/Earnings Ratio is negative for CVAC. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.11 | ||
| Fwd PE | N/A |
4.2 Price Multiples
CVAC's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. CVAC is cheaper than 99.25% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, CVAC is valued cheaper than 99.63% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.1 | ||
| EV/EBITDA | 2.79 |
4.3 Compensation for Growth
CVAC has a very decent profitability rating, which may justify a higher PE ratio.
A cheap valuation may be justified as CVAC's earnings are expected to decrease with -28.72% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-63.78%
EPS Next 3Y-28.72%
5. Dividend
5.1 Amount
CVAC does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
5.16
+0.05 (+0.98%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners6.53%
Inst Owner Change48.36%
Ins Owners0.12%
Ins Owner ChangeN/A
Market Cap1.16B
Revenue(TTM)510.51M
Net Income(TTM)193.64M
Analysts72.31
Price Target4.78 (-7.36%)
Short Float %1%
Short Ratio1.04
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-29.18%
Min EPS beat(2)-39.67%
Max EPS beat(2)-18.68%
EPS beat(4)2
Avg EPS beat(4)34.62%
Min EPS beat(4)-39.67%
Max EPS beat(4)161.44%
EPS beat(8)3
Avg EPS beat(8)-1.81%
EPS beat(12)5
Avg EPS beat(12)-8.17%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-91.68%
Min Revenue beat(2)-96.47%
Max Revenue beat(2)-86.88%
Revenue beat(4)2
Avg Revenue beat(4)75.38%
Min Revenue beat(4)-96.47%
Max Revenue beat(4)366.65%
Revenue beat(8)4
Avg Revenue beat(8)53.09%
Revenue beat(12)4
Avg Revenue beat(12)21.18%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-2.82%
PT rev (3m)-2.82%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-275%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.12%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)220.62%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-13.75%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 5.11 | ||
| Fwd PE | N/A | ||
| P/S | 1.96 | ||
| P/FCF | 5.1 | ||
| P/OCF | 4.9 | ||
| P/B | 1.71 | ||
| P/tB | 1.78 | ||
| EV/EBITDA | 2.79 |
EPS(TTM)1.01
EY19.57%
EPS(NY)-0.58
Fwd EYN/A
FCF(TTM)1.01
FCFY19.61%
OCF(TTM)1.05
OCFY20.4%
SpS2.63
BVpS3.02
TBVpS2.9
PEG (NY)N/A
PEG (5Y)N/A
Graham Number8.29
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 28.11% | ||
| ROE | 33.02% | ||
| ROCE | 33.37% | ||
| ROIC | 28.35% | ||
| ROICexc | 78.22% | ||
| ROICexgc | 88.03% | ||
| OM | 40.58% | ||
| PM (TTM) | 37.93% | ||
| GM | 94.81% | ||
| FCFM | 38.42% |
ROA(3y)-13.91%
ROA(5y)-17.17%
ROE(3y)-24.58%
ROE(5y)-30.34%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score9
Asset Turnover0.74
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | 0.18 | ||
| Debt/EBITDA | 0.14 | ||
| Cap/Depr | 44.58% | ||
| Cap/Sales | 1.55% | ||
| Interest Coverage | 91.31 | ||
| Cash Conversion | 90.71% | ||
| Profit Quality | 101.3% | ||
| Current Ratio | 6.17 | ||
| Quick Ratio | 6.16 | ||
| Altman-Z | 9.28 |
F-Score9
WACC7.18%
ROIC/WACC3.95
Cap/Depr(3y)242.45%
Cap/Depr(5y)397%
Cap/Sales(3y)81.47%
Cap/Sales(5y)93.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)170.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%18.75%
EPS Next Y-170.56%
EPS Next 2Y-63.78%
EPS Next 3Y-28.72%
EPS Next 5Y-22.5%
Revenue 1Y (TTM)675.15%
Revenue growth 3Y73.2%
Revenue growth 5Y98.42%
Sales Q2Q%-91.38%
Revenue Next Year-86.75%
Revenue Next 2Y-59.56%
Revenue Next 3Y-30.85%
Revenue Next 5Y-10.88%
EBIT growth 1Y171.44%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-152.22%
EBIT Next 3Y-32.99%
EBIT Next 5Y10.78%
FCF growth 1Y160.43%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y182.06%
OCF growth 3YN/A
OCF growth 5YN/A
CUREVAC NV / CVAC FAQ
Can you provide the ChartMill fundamental rating for CUREVAC NV?
ChartMill assigns a fundamental rating of 6 / 10 to CVAC.
What is the valuation status of CUREVAC NV (CVAC) stock?
ChartMill assigns a valuation rating of 5 / 10 to CUREVAC NV (CVAC). This can be considered as Fairly Valued.
Can you provide the profitability details for CUREVAC NV?
CUREVAC NV (CVAC) has a profitability rating of 6 / 10.
What are the PE and PB ratios of CUREVAC NV (CVAC) stock?
The Price/Earnings (PE) ratio for CUREVAC NV (CVAC) is 5.11 and the Price/Book (PB) ratio is 1.71.
Can you provide the expected EPS growth for CVAC stock?
The Earnings per Share (EPS) of CUREVAC NV (CVAC) is expected to decline by -170.56% in the next year.